openwiki-wiki/commitments.md

---
type: "Reference"
title: "Commitments"
openwiki_generated: true
---

# Commitments

Concrete work tasks, follow-ups, approvals, and scheduled items extracted from Gmail, Notion, Slack, direct mentions, and other work-relevant sources. Personal errands and life admin live in `/personal-logistics.md` instead.

## Active

### china-cde-cell-gene-therapy-rules-2026: verify CDE classification scope for Chinese pharma / CDMO conversations
- Owner: me
- Source: web-search — cisema.com 2026-07-24 (China CDE Defines Classification Rules for Cell & Gene Therapy Drugs)
- Due: unscheduled
- Status: open
- Notes: Single credible regulatory-trade source. Pull the NMPA/CDE-direct release before the next vendor sync; check whether any active CellShot-TriArm or ClinoReactor-class deals depend on the new classification scope.

### celvivo-clinoreactor-thewell-bioscience-xeno-free: verify TheWell Bioscience co-marketing signal on next CelVivo check
- Owner: me
- Source: web-search — thewellbio.com 2026-07-21 / 2026-07-23 / 2026-07-25 (Xeno-Free Cell Culture Media, Stem Cell Culture Product Guide, Apical-Out Organoids white paper — all explicitly name "CelVivo ClinoReactor™")
- Due: unscheduled
- Status: open
- Notes: First vendor-anchored CelVivo ClinoReactor signal in any Tavily pull (prior pulls returned only MO:BOT / generic organoid). TheWell Bioscience is a hydrogel-media partner; their workflow pages position ClinoReactor as the scale-up vessel for apical-out organoids + hMSC expansion. Confirm with CelVivo whether this is a sanctioned co-marketing arrangement and whether it maps to any active Chinese pharma / CDMO deal.

### china-order-no-818-clinical-translation: verify Order No. 818 (effective 2026-05-01) scope for Chinese pharma / CDMO conversations
- Owner: me
- Source: web-search — BetaLife LinkedIn 2026-07 (top score 0.779; explicitly cites "Order No. 818, effective May 1, 2026" with accelerated clinical-translation pathway); Tavily answer text corroborates; Roots Analysis re-mentions broader China cell-therapy regulatory pattern
- Due: unscheduled
- Status: open
- Notes: Single primary source (BetaLife SG LinkedIn) but the regulation itself is a published policy text — Order No. 818 creates an accelerated clinical-translation pathway at qualified hospitals for cell therapy and 3D bioprinting after demonstrating safety and preliminary efficacy. This is **the clinical-translation counterpart** to the existing `china-cde-cell-gene-therapy-rules-2026` item (which is about classification / CMC planning). Both items matter: classification scope drives dossier content vendors need to assemble; the clinical-translation pathway drives which hospitals can host first-in-human studies. Pull the NMPA / State Council Order No. 818 direct text before the next vendor sync; check whether any active CellShot-TriArm or ClinoReactor-class deal depends on whether the buyer hospital qualifies as a "qualified hospital" under the regulation.

### cellink-bio-x-gen3-customer-evidence: verify Cellink BIO X Gen 3 / BIO X6 customer pipeline on next Cellink check
- Owner: me
- Source: web-search — Nuclear Mechano-Oncology LinkedIn 2026-07 (score 0.601; "our new BIO X Gen 3 bioprinter has now been installed … first hands-on training session"); CELLINK official LinkedIn 2026-07-28 (score 0.287; BIO X6 at University of Miami 3D Bioprinting Facility); third-party market report LinkedIn 2026-07-28 (score 0.659; Cellink revenue uptick following strategic acquisitions); appellaser.ro practical selection guide 2026-07-24 (score 0.303; BIO X Gen 3 general-purpose positioning)
- Due: unscheduled
- Status: open
- Notes: First vendor-anchored Cellink signal in any Tavily pull after 5 prior pulls of zero Cellink product mentions. Four distinct sources: customer install LinkedIn (Eastern Europe), vendor LinkedIn (CELLINK U. Miami), market report, independent selection guide. Verify with Cellink whether the BIO X Gen 3 / BIO X6 nomenclature is current product naming or if one is being deprecated; whether any of the named customer accounts (Nuclear Mechano-Oncology; U. Miami 3D Bioprinting Facility) maps to active Chinese pharma R&D / CDMO opportunities. Companion to the existing `celvivo-clinoreactor-thewell-bioscience-xeno-free` item.

### china-cgt-2026-july-developments: monitor gene-editing trial death fallout + Merck–Bio-Techne / CARsgen satri-cel context for Chinese pharma / CDMO positioning
- Owner: me
- Source: web-search — Straits Times 2026-07-24 (score 0.313; patient death in China gene-editing trial draws fire); LiveScience 2026-07-24 (score 0.145; 6-year-old girl, investigation into gene-therapy regulations); SCMP 2026-07-29 (score 0.203; "Fear of policy backlash" — same-day coverage with this Tavily pull); Roots Analysis 2026-07-24 (score 0.669; Merck–Bio-Techne $11.3B acquisition June 2026 + CARsgen satri-cel CAR-T approval for stomach cancer June 2026); BioSpace 2026-07-27 (score 0.535; Summit/Merck China-first regulatory navigation)
- Due: unscheduled
- Status: open
- Notes: Material new development in the China regulatory lane — sits **on top of** the existing `china-cde-cell-gene-therapy-rules-2026` and `china-order-no-818-clinical-translation` items, not replacing them. Two positive signals (Merck–Bio-Techne acquisition; CARsgen satri-cel solid-tumor CAR-T approval) show the China CGT manufacturing environment is consolidating around advanced therapeutics. One negative signal (gene-editing trial death + published regulatory backlash) could foreshadow stricter CDE / NMPA / hospital-level oversight and tighter qualification criteria for "qualified hospitals" under Order No. 818. Together these affect: (a) qualification timelines for the CellShot-TriArm and ClinoReactor-class deals Robin has in flight, (b) which "qualified hospitals" remain eligible to host first-in-human studies, (c) whether CelVivo / 3Brain / Cellink vendor positioning for Chinese pharma R&D / CDMO accounts needs to change tone (e.g. emphasize safety documentation, IRB-grade workflows). Pull NMPA / hospital-IRB statements on the gene-editing trial case before next Chinese customer conversation.

### 3brain-coreplate-2026-conference-positioning: verify current CorePlate campaign and retrieve application material on next 3Brain check
- Owner: me
- Source: web-search — 3Brain official website plus 3Brain organization material captured through LinkedIn in Tavily pull 7 (2026-07-30); the dated result is 2026-07-25 and names ISSCR 2026 booth 412, while the company page also names ELRIG Drug Discovery booth 4. Tavily pull 11 (2026-08-03) adds a 3Brain LinkedIn post dated 2026-07-29 ("3Brain contributes to Utrecht Summer School course on Human Brain Models", score 0.808) — the **first Tavily pull where the 3Brain answer text is not mis-attribution** — and the 3Brain AG company LinkedIn page (score 0.839)
- Due: unscheduled
- Status: open
- Notes: First credible direct 3Brain evidence after five Tavily pulls dominated by an unrelated EEG-paper mis-attribution. Vendor material positions CorePlate-enabled HD-MEA for high-resolution, scalable functional readouts from iPSC neuronal/cardiac models, brain organoids, assembloids, and 3D spheroids. Pull 11 extends the vendor-channel strand to the academic / training segment (Utrecht Summer School "Human Brain Models" course) on top of the ISSCR / ELRIG conference-booth strand from pull 7. Confirm which conference posts are current, obtain the named posters / application notes / Utrecht course module, and map them to Chinese neural-organoid and pharma-screening prospects. This pull does not establish CorePlate 1W/6W load force or Sample Holder Set details.

### celvivo-clinostar-2-nams-demo-2026: verify product naming and campaign provenance on next CelVivo check
- Owner: me
- Source: web-search — Instagram snippets surfaced in Tavily pull 7 (2026-07-30): ClinoStar webinar copy (`DbaUZjIjMgK`), NexUs Locus on-site demo copy dated 2026-07-24 (`DbKYC4NBtrN`), and ClinoStar 2 NAMs positioning (`DbSl7nkoFjK`). Tavily pull 11 (2026-08-03) adds an **independent confirmation** from an Indian distributor event page (labindia-analytical.com News & Events, score 0.696) that CelVivo is exhibiting at Thailand Lab 2026 (Bangkok, 2026-09-02 → 2026-09-04) and that `ClinoStar 2` is current product naming with oxygen regulation as a distinguishing feature
- Due: unscheduled
- Status: open
- Notes: Watchlist lead, not a confirmed launch or customer win. Verify that the posts come from CelVivo or an authorized distributor, whether `ClinoStar 2` is current official product naming, and whether the NexUs Locus live demo produced reusable data or contacts. Pull 11's labindia-analytical.com result is the **first non-Instagram, named-event confirmation** of ClinoStar 2 + Thailand Lab 2026; treat it as independent corroboration, not vendor-direct. The result set does not support Tavily's “installed base” language; one malformed duplicate URL was discarded.

### cellink-volumetric-lumen-x-release: verify CELLINK × Volumetric new Lumen X release on next Cellink check
- Owner: me
- Source: web-search — Tavily pull 11 (2026-08-03) top hit on `Cellink BIO X bioprinter 2026`: 3DPrint.com 2026-07-28 (score 0.819) "CELLINK and Volumetric Release New Lumen X for Lumen X Bioprinting". Tavily answer text corroborates and adds BioMET '26 Vellore India (2026-08-05 → 2026-08-07) showcase detail. Companion evidence: Cellink LinkedIn 2026-07-29 (score 0.762) BioMET '26 exhibiting post; CELLINK Facebook 2026-07-28 (score 0.632) second-conference post
- Due: unscheduled
- Status: open
- Notes: **First credible direct Cellink product / partnership release evidence on the Robin portfolio** after 10 prior Tavily pulls dominated by mis-attribution or BIO X Gen 3 / BIO X6 customer evidence (see existing `cellink-bio-x-gen3-customer-evidence`). Lumen X is in Robin's portfolio table ("Cellink — BIO X / BIONOVA X / Lumen X"). Verify with Cellink: (a) what is the relationship between CELLINK and Volumetric — co-marketing, OEM, distribution, or full acquisition; (b) is "New Lumen X" a distinct SKU from the original Lumen X (volumetric DLP) or a refresh; (c) does BioMET '26 Vellore presence map to any active Chinese pharma R&D / CDMO / biotech opportunities (likely India-channel rather than China-channel — adjacent to Robin's region); (d) does the existing `cellink-bio-x-gen3-customer-evidence` commitment's BIO X6 at U. Miami installation narrative change in light of this release.

### itx-24h-host-build-2026-q3: finish assembly + Ubuntu + Hermes install on Robin's 24h host (paused since hardware is 10/11 arrived)
- Owner: me
- Source: git-repo — `03-Resources/ITX-24h-Host/ITX_24h_Host_v18_Config_2026-07-31.md` (Obsidian vault, untracked as of fetch 2026-07-31T18:08:12Z)
- Due: unscheduled (waiting for the last #8 / #9 cable parts on hand; once on hand, finish the assembly + software stack)
- Status: open
- Notes: Personal-infra work item (workflow-tooling priority LOW), not vendor-anchored — logged here because it is source-anchored to Robin's actual vault work per the brief's commitments.md rule ("only real Robin commitments"). Plan: mATX + i5-12400 + DDR4-2666 32G + 板载 Realtek 1Gb + Intel PRO/1000 GT (¥2,985.82, 10/11 parts on hand). Two 网卡 VLAN: 192.168.31.100 → 主力机 Win 11 SSH, 10.10.10.254 → 主力 NAS RAGFlow. Post-assembly steps: Ubuntu Server 22.04 LTS install, partition `/` (GM7 512G) + `/data` (mSATA 512G), Docker, dual-NIC 静态 IP, 主力机 SSH key 免密, NAS RAGFlow API 接入, 安装 Hermes Agent, 24h 跑功耗 soak test. The host has no vendor-product overlap; not promoted to `/themes.md` row because that index is reserved for recurring workflow signals.

<!--
Structure for new entries:

### <topic-key>: <short title>
- Owner: me | team | other:<name> | unknown
- Source: <connector> — <short ref>
- Due: YYYY-MM-DD or unscheduled
- Status: open | waiting | blocked | done
- Notes: <optional context>

## By owner

### Mine
- (none)

### Team
- (none)

### Other
- (none)
-->

## Completed recently

<!--
Move done items here with a Completed: date so they stay auditable without cluttering Active.
-->